SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Lifesciences informs about press release

01 Oct 2022 Evaluate

Zydus Lifesciences has informed that it enclosed a copy of press release dated October 1, 2022 titled ‘Zydus receives final approval from the USFDA for Sildenafil for Oral Suspension’.

The above information is a part of company’s filings submitted to BSE.

Zydus Lifesciences Share Price

1150.80 -9.05 (-0.78%)
10-Jul-2026 11:02 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1938.60
Dr. Reddys Labs. 1247.70
Cipla 1450.80
Zydus Lifesciences 1150.80
Lupin 2511.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: